joining provide to Thanks, afternoon to on you progress Jody. and thank opportunity pleased everyone this have update business. our for us. share an Good I'm and our
of vascular market the than majority the of research combined CTOs $XXX the figure market disease, represents occlusions differentiated for large in chronic crossing and our $XXX products for more atherectomy the of We total million. value million and Atherectomy opportunity, are excited address growing or the approximately third-party estimating XXXX. this at peripheral We at about PAD. market treatment updated obtained the the recently or artery
for the and with advantages initiatives I the required an we update our pivotal distinct will for Today, our in and appropriate work we reminder, indication secure crossing on has begin clinical success. product engineering a to on a and FDA CTOs, for vascular believe competitive to develop outline indication. a atherectomy for progress I As will the clearance trial our FDA line have business. are important market progress
We are our to catheters as efforts life shelf as making those our related future the progress efforts well extend development of to catheters. with great
of As core namely inner and of previously into reported, introduction life, we the elements have coating. identified the degradation unwanted water root limited two, the the causes catheter's the the one, of catheter's shelf
efforts include process six at in-house test to shelf and Recent and are accelerated sterilization Our changes. mitigate aging life issues both of data a encouraging very least material, support months.
beyond an continuing develop our to set submission support shelf aging data life test to to FDA We a potentially robust more six extend and are months.
continues catheter. work the on to generation next advance our also team DABRA Our
resistant, evaluated more concerning this As performance a it and navigating cerebral reminder, designs catheter jacket workshop received with We and hands-on torturous the potential late catheter gen kink but anatomy. and of feedback the next at with in its a vascular deliverable prototype new incorporates to constructive improvement make a physicians braided design. over XXXX
expect in we XXXX. subsequently And complete second engineering We the clearance. to for will this for work catheter of half the FDA submit
is the We also an standard and improved the XXXX are in the project compatibility regarding features work leverages several goal. described compatible performance are with great prototypes positive with guidewire. the catheter and a previously project that with workshop we this incorporating the in received We reporting This of catheter feedback hands-on evaluated design. DABRA during catheter of added progress final late usability design the
the the end work complete the compatible for XXXX. catheters overall of We to before expect guidewire design
several initiated Pharos improve Lastly, the have projects laser both DABRA we the and development laser to front, systems. development on
upgrade Specifically, CPU we and the life. have projects underway gas extend the to
the initial to in systems laser introduce XXXX. upgraded expect We
enrolled and we sites up is subjects. to for XX our clinical to clinical as in approved our XX last indication Currently of have in the Since XX FDA we enrolled platform, an trial process. cleared an mid-November, stages this a have Moving continue make subjects on total investor to for subjects to-date. various five enrollment and in The three additional are here atherectomy for DABRA good sites XXX progress to call the obtain for additional been qualification sites well. study of study
in XX days. unpredictable sites next note study, the the subjects stages to we One begin of the is approval three We these to enrollment resume the final and enrolling it qualification we completed catheter. impact with pandemic of of current in be the on of to to commercial requesting Due the COVID-XX will business. final the One expect filing shipments regarding cannot DABRA estimate FDA the a precision vascular completed. when recently
stated XXXX. month. met you FDA our in As we stopped On may by this this to to catheter in this belief earlier recall, would quarterly we voluntarily that we due at submitted life resolve call, timeline internal the shipments XXXX this shelf in September We the of quarter filing that detected our of data. the variations first we issue our November time
our we and post both a We footprint the in dermatology a executing announce joined dermatology leader believe market environment. a a contract representatives, QX. manner our latter expanding grow Ra efficient to pleased I years to our capital track refining strategy new for being business, am XX in a business direct Turning and commercial COVID-XX this commercial record aesthetics is of and success. basis. experience Medical that commission has can and on His of paid in on focus hires but Jon with commercial the by carefully Jon solely current Bullock
of COVID-XX, as Although continues experience sequential did impacted by to XXXX growth purchase QX. a capital in from dermatology QX customers many equipment, acquisition business or our quarter dermatology be we the revenue the delay to
a pre-COVID. of revenue our business As roughly year generated $X dermatology million $X reminder, to a million
assurance we items to fourth quality comprised operating preventive standard with no quality a On system on also completed pleased XXX that front, and procedures, focus of the a a management with a supplier the equipment successfully maintenance, calibrations plan observations. system wide BSI in that addressed quality report items. of we completed and quality. improvement audit quarter I'm quality the was within during of of plan The XXXX, range status January
cooperated by Finally, U.S. tentative disclosed executed, a attorneys settlements settlement investigations compliance the of remain to as resolve at fully state expectations of officer to into hired to connection and XXXX conducted False disclosed committed certain the asserted been that and of We these by in Department agreements previously investigation participating company. investigation related by an previously previously with quarter if Act began We the And disclosed, with Civil our forward. various reached state the of also the a investigations, XXXX. states Justice internal starting federal we agreement the the programs the compliance have with the the resolve second with that cooperate these end matters. meeting I reached that oversee In pleased recently We Claims general. claims settlement, company resolved with entered that am governments. going
to financial discuss will to I Andrew? Andrew the turn call results. Now, over our
